Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 12,734 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Elpipodect (MK-8189) Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)

NCT06626464
View directory record Official record
Conditions
Healthy
Interventions
[14C]Elpipodect
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Terminated Not applicable Interventional

Focal Laser Ablation of Prostate Cancer: A Feasibility Study Using MRI/US Image Fusion for Guidance

NCT06047509
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal Laser Ablation
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects

NCT03836599
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Verinurad, Allopurinol, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 21, 2026, 4:26 AM EDT
Recruiting Phase 1Phase 2 Interventional

Muscle Fiber Fragment Treatment for Urinary Incontinence

NCT01953263
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Autologous Muscle Fiber Fragments
Other
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

NCT00090363
View directory record Official record
Conditions
Prostate Cancer
Interventions
ZD4054 15 mg, Placebo, ZD4054 10 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Tucson, Arizona • Los Angeles, California • Gainsville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

NCT03552393
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Mircera
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Months to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Loma Linda, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 21, 2026, 4:26 AM EDT
Active, not recruiting Phase 3 Interventional Results available

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
20
States / cities
Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed No phase listed Observational

Developmental Epidemiological Study of Children Born Through Reproductive Technology

NCT03799107
View directory record Official record
Conditions
Infertility, Infertility, Female, Infertility, Male, Infertility Primary, Infertility Secondary, Infertility Unexplained
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
4 Years and older
Enrollment
2,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Savolitinib vs. Sunitinib in MET-driven PRCC.

NCT03091192
View directory record Official record
Conditions
Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms, Kidney Diseases, Neoplasms by Site, Enzyme Inhibitors, Protein Kinase Inhibitors
Interventions
Savolitinib, Sunitinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
8
States / cities
La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Withdrawn Phase 1 Interventional

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

NCT05655598
View directory record Official record
Conditions
Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC, Soft Tissue Sarcoma, Endometrial Cancer, Bladder Cancer
Interventions
Palbociclib Oral Product, TAS-116
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 4:26 AM EDT
Completed No phase listed Observational

Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

NCT03014063
View directory record Official record
Conditions
Septic Shock
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Mosliciguat in Healthy, Adult Males

NCT07185321
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Mosliciguat, 14C mosliciguat, Dry Powder Inhaler
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Not applicable Interventional Results available

Facilitating Communication Study

NCT03721952
View directory record Official record
Conditions
Chronic Disease, Neoplasm Metastasis, Lung Neoplasm, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Multiple Organ Failure, Health Care Quality, Access, and Evaluation, Intensive Care Units, Palliative Care, Health Services, Palliative Care, Patient Care, Lung Diseases, Cerebrovascular Disorders, Brain Injuries
Interventions
Facilitator-Based Intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

NCT04383938
View directory record Official record
Conditions
Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC, Urothelial Carcinoma, Advanced Solid Tumor
Interventions
APR-246 (eprenetapopt) + Pembrolizumab
Drug
Lead sponsor
Aprea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

H-22411: BOTOX® for Peyronie's Disease

NCT00812838
View directory record Official record
Conditions
Peyronie's Disease
Interventions
100 units of Botulinum Toxin Type A, Preservative free normal saline, 100 units Botulinum Toxin A
Drug · Other
Lead sponsor
Mohit Khera
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia

NCT00605319
View directory record Official record
Conditions
Bladder Outlet Obstruction
Interventions
Toviaz (Fesoterodine)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 99 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 21, 2026, 4:26 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer

NCT01389830
View directory record Official record
Conditions
Advanced Cancers
Interventions
Telephone Survey
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 21, 2026, 4:26 AM EDT
Recruiting No phase listed Observational

A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

NCT07677267
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 115 Years · Male only
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Not yet recruiting Not applicable Interventional

Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease

NCT05558267
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Standard Table Salt, Salt Substitute
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Not applicable Interventional Results available

The Personal Patient Profile Decision Support for Patients With Bladder Cancer

NCT05033067
View directory record Official record
Conditions
Bladder Cancer
Interventions
P3BC
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Terminated Not applicable Interventional

Ultrasound Image Fusion for Placement of Sacral Quadripolar Leads

NCT01054534
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Placement of interstim lead
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 90 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 21, 2026, 4:26 AM EDT
Not listed Phase 1 Interventional

A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

NCT02950064
View directory record Official record
Conditions
Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
Interventions
BTP-114
Drug
Lead sponsor
Placon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Sarasota, Florida • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 21, 2026, 4:26 AM EDT
Recruiting No phase listed Observational

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

NCT07096999
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 21, 2026, 4:26 AM EDT
Completed Phase 3 Interventional

A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes

NCT00076232
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity, Herpes Genitalis
Interventions
Acyclovir, Acyclovir placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
3,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
San Francisco, California • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 30, 2010 · Synced Oct 21, 2026, 4:26 AM EDT